AMR Centre teams up to tackle gonorrhoea

  20 March 2020

The project is targeting multi-drug resistant gonorrhoea and will see AMRC undertake pre-clinical development to drive Microbiotix’s novel mechanism drug, a Trans T ribosome rescue inhibitor, through lead optimisation and into pre-clinical nomination.

The collaboration is currently receiving $2.86 million in grant funding and could receive an additional $16 million if certain development milestones are met. The funding is being offered by CARB-X, an organisation which helps accelerate global antibacterial projects.

Author(s): European Pharmaceutical Manufacturer
Healthy Patients   Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!